FDA approves Bayer’s electronic autoinjector for MS therapy
The first electronic automatic injector to deliver a drug for the most common form of multiple sclerosis received approval from the U.S. Food and Drug Administration on Friday. The injection delivers Betaseron, a disease-modifying drug approved 22 years ago by the FDA for relapsing forms of the incurable, often disabling disease of the central nervous system. The new device, called Betaconnect, will be available in early 2016, said Germany's Bayer AG, which developed the injector and sells the drug.